BREAST AND GYNECOLOGIC CANCERS
Breast cancer is one of the most common types of cancer affecting women, followed by gynecologic cancers, including ovarian, endometrial/uterine, cervical, vulvar and vaginal cancer. Although surgery, radiation, endocrine treatment and chemotherapy are currently major treatment regimens for these cancers, targeted therapy (e.g. HER2 antibodies and PARP inhibitors) and immunotherapy are emerging options for subsets of eligible patients. Some women with breast cancer may also be at risk for developing other cancers, including ovarian cancer, especially when carrying a germline mutation of the BRCA gene. Therefore, comprehensive genetic testing is beneficial for breast and gynecologic cancer patients seeking precision medicine and to evaluate their genetic predisposition to other cancer types.
MAMECAN™
Targets 68 key genes in breast cancer
- Comprehensive testing of HER2(ERBB2) variants and ER mutations, dysregulation of PI3K-mTOR signaling pathway, and BRCA1/2 deficiency
- Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers
- Reveals potential resistance mechanism(s) to current therapy
- Assesses genetic predisposition to cancers
- Optional PD-L1 immunohistochemistry (IHC) test to better guide immunotherapy decisions for advanced triple-negative breast cancer (TNBC) patients
WHO IS IT FOR
- Breast cancer patients seeking precision medicine
- Breast cancer patients resistant to endocrine therapy, chemotherapy or targeted therapy
SAMPLE TYPES
Tumor tissue (FFPE block/slides, or frozen tissue)
Fine needle biopsy
Liquid biopsy (plasma and others)
GYNOCAN™
Targets 70 key genes in gynecologic cancers
Cancer types: ovarian, endometrial/uterine, cervical, vulvar and vaginal cancer
- Assesses key genes including BRCA1/2 to predict response to PARP inhibitors
- Evaluates microsatellite instabilities (MSI) and mismatch repair deficiency (dMMR) to better inform immunotherapy decisions
- Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers
- Assesses genetic predisposition to cancers
- Optional PD-L1 immunohistochemistry (IHC) test to better guide immunotherapy decisions for advanced cervical cancer patients
WHO IS IT FOR
- Gynecologic cancer patients seeking precision medicine
- Gynecologic cancer patients resistant to chemotherapy or targeted therapy
SAMPLE TYPES
Tumor tissue (FFPE block/slides, or frozen tissue)
Fine needle biopsy
Liquid biopsy (plasma and others)
LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.
Learn more about our products and services or contact us today to discuss how we can partner together.